Effect of Cytomegalovirus Infection on Survival of Older Kidney Transplant Patients (D+/R+): Impact of Valganciclovir Prophylaxis Versus Preemptive Therapy.

[1]  A. Caliendo,et al.  The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation , 2010, Transplantation.

[2]  G. Wolf,et al.  Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: 1-Year Results of a Randomized Clinical Trial , 2012, Transplantation.

[3]  D. Navarro,et al.  GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. , 2011, Enfermedades infecciosas y microbiologia clinica.

[4]  P. Religa,et al.  Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  F. Luan,et al.  Universal Prophylaxis is Cost Effective in Cytomegalovirus Serology-Positive Kidney Transplant Patients , 2011, Transplantation.

[6]  E. Mueller,et al.  Prolonged Prophylaxis With Valganciclovir Is Cost Effective in Reducing Posttransplant Cytomegalovirus Disease Within the United States , 2010, Transplantation.

[7]  S. Bunnapradist,et al.  Cytomegalovirus Serostatus Pairing and Deceased Donor Kidney Transplant Outcomes in Adult Recipients With Antiviral Prophylaxis , 2010, Transplantation.

[8]  T. Buclin,et al.  Ganciclovir exposure under a 450 mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplantation: a prospective study , 2010, Clinical transplantation.

[9]  D. Brennan,et al.  Impact of Prophylactic Versus Preemptive Valganciclovir on Long-Term Renal Allograft Outcomes , 2010, Transplantation.

[10]  C. Forconi,et al.  Revisiting the effects of CMV on long-term transplant outcome , 2010, Current opinion in organ transplantation.

[11]  D. Abramowicz,et al.  The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High‐Risk Kidney Transplant Recipients , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  Sarah E. Jackson,et al.  Cytomegalovirus Infection Reduces Telomere Length of the Circulating T Cell Pool , 2010, The Journal of Immunology.

[13]  Angela M Caliendo,et al.  International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. , 2010, Transplantation.

[14]  A. Pera,et al.  Cytomegalovirus in the Elderly: Impact of Cytomegalovirus Infection on Senescence of the Immune System , 2010 .

[15]  R. Colvin,et al.  Viral Infection Induces De Novo Lesions of Coronary Allograft Vasculopathy Through a Natural Killer Cell‐Dependent Pathway , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[16]  R. Solana,et al.  Age-Dependent Association between Low Frequency of CD27/CD28 Expression on pp65 CD8+ T Cells and Cytomegalovirus Replication after Transplantation , 2009, Clinical and Vaccine Immunology.

[17]  C. Orosz,et al.  Disruption of Murine Cardiac Allograft Acceptance by Latent Cytomegalovirus , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  B. Gersh.  Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study , 2008 .

[19]  H. Valantine,et al.  T-Cell Immunity to Subclinical Cytomegalovirus Infection Reduces Cardiac Allograft Disease , 2006, Circulation.

[20]  D. Snydman,et al.  Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  M. Schnitzler,et al.  Prophylactic Versus Preemptive Oral Valganciclovir for the Management of Cytomegalovirus Infection in Adult Renal Transplant Recipients , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  J. Preiksaitis,et al.  Canadian Society of Transplantation Consensus Workshop on Cytomegalovirus Management in Solid Organ Transplantation Final Report , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[23]  G. Opelz,et al.  Cytomegalovirus Prophylaxis and Graft Outcome in Solid Organ Transplantation: A Collaborative Transplant Study Report , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  G. Pawelec,et al.  Dysfunctional CMV-specific CD8+ T cells accumulate in the elderly , 2004, Experimental Gerontology.

[25]  H. Valantine.  The Role of Viruses in Cardiac Allograft Vasculopathy , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  P. Changelian,et al.  The Novel JAK‐3 Inhibitor CP‐690550 Is a Potent Immunosuppressive Agent in Various Murine Models , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  G. Pawelec,et al.  Large Numbers of Dysfunctional CD8+ T Lymphocytes Bearing Receptors for a Single Dominant CMV Epitope in the Very Old , 2003, Journal of Clinical Immunology.

[28]  H. Valantine.  Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant “atheroma” , 2003, Transplantation.

[29]  R. Cawthon,et al.  Association between telomere length in blood and mortality in people aged 60 years or older , 2003, The Lancet.

[30]  N. Samani,et al.  Telomere shortening in atherosclerosis , 2001, The Lancet.

[31]  Nina Singh,et al.  Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  T. Merigan,et al.  Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. , 1999, Circulation.

[33]  K. Lemström,et al.  Cytomegalovirus infection-enhanced cardiac allograft vasculopathy is abolished by DHPG prophylaxis in the rat. , 1997, Circulation.

[34]  R. Rubin.  The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. , 1989, JAMA.

[35]  A. Imamura,et al.  [Cytomegalovirus infection in renal transplant recipients]. , 1988, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.